Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.37 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PRKCB | P05771 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | PRKCH | P24723 | 1/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4764726 | 0.84 | SMN1; SMN2 (0.46) | ROCK2ROCK1PKN2GBA1ALDH1A1 | |
| SCHEMBL4772049 | 0.84 | LMNA (0.47) | GBA1KDM4EALDH1A1MAPTMAPK1 | |
| SCHEMBL4774345 | 0.83 | GBA1 (0.47) | ROCK2ROCK1PKN2GBA1KDM4E | |
| Hydrochloric Acid SCHEMBL6860795 | 0.83 | SMN1; SMN2 (0.45) | ROCK2ROCK1PKN2GBA1ALDH1A1 | |
| SCHEMBL14102714 | 0.81 | ROCK2 (0.43) | ROCK2ROCK1PKN2GBA1KDM4E | |
| SCHEMBL4766376 | 0.81 | KMT2A (0.46) | GBA1KDM4EALDH1A1MAPTADORA3 | |
| SCHEMBL4766020 | 0.78 | GBA1 (0.43) | ROCK2ROCK1PKN2GBA1KDM4E | |
| SCHEMBL4774328 | 0.78 | GBA1 (0.43) | ROCK2ROCK1PKN2GBA1KDM4E | |
| SCHEMBL4774179 | 0.74 | GBA1 (0.52) | ROCK2ROCK1PKN2GBA1KDM4E | |
| SCHEMBL4769201 | 0.74 | SMN1; SMN2 (0.45) | ROCK2ROCK1PKN2GBA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | ROCK2 3313/4885ROCK1 2976/4885PKN2 1204/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | ROCK2 1825/4885ROCK1 1087/4885PKN2 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.